Search

Zai Lab Ltd ADR

Closed

SectorHealthcare

24.08 0.21

Overview

Share price change

24h

Current

Min

23.99

Max

24.2

Key metrics

By Trading Economics

Income

191K

-51M

Sales

6.7M

106M

EPS

-0.46

Profit margin

-47.808

Employees

1,784

EBITDA

-2.1M

-46M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+62.94% upside

Dividends

By Acuity

Next Earnings

5 lis 2026

Market Stats

By TradingEconomics

Market Cap

892M

2.9B

Previous open

23.87

Previous close

24.08

News Sentiment

By Acuity

38%

62%

89 / 339 Ranking in Healthcare

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 wrz 2026, 12:41 UTC

News

Solana is trading higher as investor interest in cryptocurrency strengthens, aided by positive momentum from Ethereum and Pepeto's successful presale raising $10.96 million.

12 wrz 2026, 00:06 UTC

Macro News
Macro Event
News

Bitcoin trades higher, nearing $79,000, as the market rebounds from $388 million in liquidations amid inflation concerns and declining crude oil prices.

12 wrz 2026, 00:01 UTC

News

Kroger Co reported mixed second-quarter results, with shares lower in after-market trading. EPS guidance for the fiscal year is set between $5.10 and $5.30.

12 wrz 2026, 00:01 UTC

Social Media
News

Scholar Rock Holding Corp shares rose in after-market trading following FDA approval of ISEMBYLD for spinal muscular atrophy, with commercial supply set to begin shortly.

12 wrz 2026, 00:01 UTC

News

Nasdaq Inc announced a $100 million investment in Payward to develop blockchain-based equities, launching Nasdaq Equity Tokens in 2027. Shares traded higher in after-market hours.

12 wrz 2026, 00:01 UTC

News
Social Media

Johnson & Johnson shares rose in after-hours trading amid reports of Apollo Global Management discussing a $20 billion acquisition of its DePuy Synthes unit.

12 wrz 2026, 00:01 UTC

Social Media
News

Corning Inc shares fell in after-market trading following a $2 billion common stock offering announcement, raising investor concerns over potential dilution.

11 wrz 2026, 23:56 UTC

News

Ionis Pharmaceuticals received FDA approval for ZANVASTRO. Shares are higher in after-market trading, reflecting positive sentiment despite a setback in a partnered trial.

11 wrz 2026, 23:41 UTC

News
Social Media

Johnson & Johnson shares higher after news of Apollo Global Management's interest in acquiring its $20 billion orthopedics unit, DePuy Synthes.

11 wrz 2026, 23:26 UTC

News

Bentley Systems declared a quarterly dividend of $0.07 per share, scheduled for September 29, 2026, with shares trading higher in after-market hours.

11 wrz 2026, 23:16 UTC

News

Carriage Services Inc shares higher in after-hours trading, following a Friday close. Analysts set an average price target of $51.00, indicating potential upside.

11 wrz 2026, 23:06 UTC

Macro Event
News

Ethereum is higher in Friday's session, recovering after four days of declines. The asset remains above its 20-day moving average amid rising inflation pressures.

11 wrz 2026, 23:06 UTC

Macro Event
News

Ethereum is rising during Friday's session, supported by recent inflation data and fluctuating crude oil prices. The asset remains above its 20-day moving average.

11 wrz 2026, 23:01 UTC

Social Media
News

Oracle Corp's after-market shares declined following a $700 million expansion of its restructuring plan, raising total costs to $2.8 billion amid financial pressures.

11 wrz 2026, 23:01 UTC

News

Nasdaq Inc. shares rose in after-market trading following a $100 million investment in Payward to develop Nasdaq Equity Tokens, set to launch in 2027.

11 wrz 2026, 23:01 UTC

Social Media
News

Corning Inc shares fell in after-market trading following a $2 billion stock offering announcement, raising investor concerns about potential dilution.

11 wrz 2026, 22:51 UTC

News
Social Media

Scholar Rock Holding Corp gains after FDA approves ISEMBYLD for spinal muscular atrophy, with a U.S. launch set to begin shortly.

11 wrz 2026, 22:01 UTC

News

Estée Lauder Companies secured a legal win against Walmart over counterfeit products, but shares are trading lower in after-market hours amid ongoing retail sector concerns.

11 wrz 2026, 21:31 UTC

News

Warner Bros Discovery Inc. shares are higher in after-market hours following reports of Paramount's settlement talks with state attorneys general over its acquisition proposal.

11 wrz 2026, 20:51 UTC

News

Ralph Lauren Corp's Board declared a quarterly dividend of $1.00 per share, and shares are trading higher in after-market hours.

11 wrz 2026, 20:09 UTC

News

1-800-Flowers.Com Inc shares are lower after reporting Q2 revenue of $293.1 million and a non-GAAP loss of $0.80 per share.

11 wrz 2026, 20:09 UTC

News

Century Communities plans to open Grand Oaks of Callaway in Florida on September 26, featuring homes starting from the upper $200s. Shares are gaining.

11 wrz 2026, 20:09 UTC

News

Columbia Sportswear appoints Peter Rauch as President of Mountain Hardwear, effective September 28. Shares are higher today, despite pulling back from an earlier session high.

11 wrz 2026, 20:09 UTC

News

Clear Secure shares are lower after DA Davidson analyst Wyatt Swanson cut the price target to $45.00 from $55.00 while maintaining a Neutral rating.

11 wrz 2026, 20:09 UTC

News

Carvana Co's shares are lower today, continuing a downward trend amid institutional investment activity and persistent inflation pressures indicated by recent CPI data.

11 wrz 2026, 20:09 UTC

News

Ultragenyx Pharmaceutical shares are lower as Bronstein, Gewirtz & Grossman, LLC, initiates an investigation following disappointing Phase 3 study results for apazunersen.

11 wrz 2026, 20:09 UTC

News
Social Media
Correlated Moves

Snowflake Inc. shares are declining amid insider selling by director Benoit Dageville, who sold 50,000 shares at $335.72 on September 9.

11 wrz 2026, 20:09 UTC

News
Social Media

Advanced Micro Devices shares are higher today following positive growth projections for its server and data center businesses, potentially exceeding $65 billion by Q4 2026.

11 wrz 2026, 20:09 UTC

News

Intercontinental Exchange sponsors the 9/11 Day of Service initiative. Shares are advancing during Friday's trading, reflecting positive momentum since Thursday's close.

11 wrz 2026, 20:09 UTC

News
Social Media

Marvell Technology reports fiscal Q2 revenue of $2.73 billion, exceeding estimates. Shares are higher amid strong demand for AI networking and advanced technologies.

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

62.94% upside

12 Months Forecast

Average 39.333 USD  62.94%

High 45 USD

Low 36 USD

Based on 3 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Sentiment

By Acuity

89 / 339 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat